Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07448480

Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas

Sponsor: Blokhin's Russian Cancer Research Center

View on ClinicalTrials.gov

Summary

GLIOTARG trial is a large single-center observational cohort study designed to investigate chemotherapy and targeted therapy outcomes in recurrent malignant gliomas. The study includes patients with molecularly confirmed diagnoses according to the World Health Organization (WHO) 2021 classification of Central Nervous System (CNS) tumors: glioblastomas (IDH-wildtype, WHO grade 4), astrocytomas (IDH-mutant, WHO grade 3-4), and pleomorphic xanthoastrocytomas (WHO grade 2-3).

Official title: Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas: Large Single-Center Observational Cohort Study (GLIOTARG)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

1000

Start Date

2026-02-01

Completion Date

2027-10-01

Last Updated

2026-03-04

Healthy Volunteers

No

Interventions

DRUG

Bevacizumab-Containing Regimens

Patients receiving any line of therapy that includes bevacizumab (alone or in combination with other agents such as temozolomide, irinotecan, lomustine, carboplatin, etc.)

DRUG

Non-Bevacizumab Regimens

Patients receiving conventional chemotherapy without bevacizumab (including temozolomide monotherapy, PCV regimen, nitrosoureas, platinum compounds, etc.)

DRUG

BRAF ± MEK Targeted Therapy

Patients harboring BRAF mutations receiving targeted therapy with BRAF inhibitors (dabrafenib, vemurafenib) alone or in combination with MEK inhibitors (trametinib, cobimetinib), with or without concomitant chemotherapy

Locations (1)

Blokhin's Russian Cancer Research Center

Moscow, Russia